ランキング
価格
はじめての方へ
ログイン
無料体験
米国企業
Viridian Therapeutics, Inc.\DE
Viridian Therapeutics, Inc.\DE
VRDN
時価総額
PER
マイリストに追加
マイリストに追加
サマリーテーブルに戻る
十億
百万
千
USD
EUR
年次
四半期
Download CSV
損益計算書
バランスシート
キャッシュフロー
2014年
12月31日
2015年
12月31日
2016年
12月31日
2017年
12月31日
2018年
12月31日
2019年
12月31日
2020年
12月31日
2021年
12月31日
2022年
12月31日
2023年
12月31日
Net loss
-8
-11
-13
-27
-33
-42
-111
-79
-130
-238
Issuance of common stock under license agreement
-
0
-
-
-
-
6
8
-
6
Share-based compensation expense
4
3
2
2
4
4
4
14
20
67
Amortization of Debt Issuance Costs and Discounts
-
-
-
-
-
-
-
-
0
0
Depreciation and amortization
0
0
0
0
0
0
0
0
0
1
Accretion and amortization of premiums and discounts on available-for-sale securities
-
-
-
-
0
0
-0
-1
0
11
Realized gain on investments
-
-
-
-
-
-
-
0
-
-
Loss on sale of equipment
-
-
-
-
-
-
-
-0
-
-0
Net loss on extinguishment of debt
-
-
-71,000
-
-
-
-
-
-
-0
Non-Cash Lease Expense
-
-
-
-
-
-
-
-0
0
0
Debt Extinguishment Expense
-
-
-
-
-
-
-
-
-
1
Prepaid expenses and other assets
-0
-0
-0
1
-0
-0
0
1
3
2
Accounts payable
-
-
-
-0
-0
1
-0
2
12
-12
Accrued and other liabilities
-
-
-
-2
1
1
5
1
8
5
Unbilled revenue
-
-
-
-
-
-
-
-
-0
-
Deferred revenue
-
-
-
-
-
-
-
1
-0
-0
Loss on sale of equipment
-
-
-
-
-
-
-
-0
-
-0
Non-Cash Lease Expense
-
-
-
-
-
-
-
-0
0
0
Other non cash items
-
-
-
-
-
-
-0
-
-
-0
Prepaid expenses and other assets
-0
-0
-0
1
-0
-0
0
1
3
2
Accounts payable
-
-
-
-0
-0
1
-0
2
12
-12
Accrued and other liabilities
-
-
-
-2
1
1
5
1
8
5
Unbilled revenue
-
-
-
-
-
-
-
-
-0
-
Deferred revenue
-
-
-
-
-
-
-
1
-0
-0
Net cash used in operating activities
-2
-7
-7
-28
-27
-36
-30
-55
-94
-184
Purchases of short-term investments
-
-
-
-
-
-
-
188
223
408
Proceeds from sales and maturities of short-term investments
-
-
-
-
-
-
-
-
109
315
Proceeds from sale of property and equipment
-
-
-
-
-
-
-
0
-
-
Purchases of property and equipment
0
0
0
0
0
0
0
0
1
1
Net cash used in investing activities
-0
-0
-0
1
-30
28
-50
-74
-115
-94
Proceeds from Issuance of Common Stock
-
-
-
-
-
-
-
-
-
15
Common Stock
-
-
-
-
-
-
1
7
19
7
Preferred Stock
-
-
-
-
-
-
5
1
3
5
Payment of issuance costs
-
-
-
-
-
0
-
-
-
-
Proceeds from Issuance of Private Placement
-
-
-
-
-
-
-
-
-
76
Proceeds from Issuance of Convertible Preferred Stock
-
-
-
-
-
-
91
-
44
-
Common Stock
-
-
-
-
-
-
1
7
19
7
Preferred Stock
-
-
-
-
-
-
5
1
3
5
Payment of issuance costs
-
-
-
-
-
0
-
-
-
-
Proceeds from Warrant Exercises
-
-
-
-
-
-
-
-
1
2
Proceeds from Issuance of Convertible Preferred Stock
-
-
-
-
-
-
91
-
44
-
Proceeds from Issuance of Secured Debt
-
-
-
-
-
-
-
-
5
15
Proceeds from Warrant Exercises
-
-
-
-
-
-
-
-
1
2
Payment of debt issuance costs
-
-
-
-
-
-
-
-
0
-
Proceeds from Issuance of Secured Debt
-
-
-
-
-
-
-
-
5
15
Proceeds from Stock Options Exercised
-
-
-
0
0
0
-
1
3
19
Payment of debt extinguishment costs
-
-
-
-
-
-
-
-
-
1
Proceeds from Stock Plans
-
-
-
-
-
-
-
0
0
1
Payment of debt issuance costs
-
-
-
-
-
-
-
-
0
-
Net cash provided by financing activities
7
13
-0
52
42
0
101
125
322
226
Proceeds from Stock Options Exercised
-
-
-
0
0
0
-
1
3
19
Proceeds from Stock Plans
-
-
-
-
-
-
-
0
0
1
Net cash provided by financing activities
7
13
-0
52
42
0
101
125
322
226
Net increase (decrease) in cash and cash equivalents
-
-
-
-
-
-8
21
-4
113
-53
Interest paid
-
-
-
-
0
1
0
-
0
1
Capital Expenditures Incurred but Not yet Paid
-
-
-
-
-
-
-
0
0
-
Amortization Of Stock Issuance Costs
-
-
-
-
-
-
0
0
0
-
Stock Issuance Costs Included In Accrued Liabilities
-
-
-
-
-
-
-
-
-
0
Stock Issuance Costs Included In Accounts Payable
-
-
-
-
-
-
-
-
-
0
Notes Reduction
-
-
-
-
-
-
-
-
-
5
Notes Issued
-
-
-
-
-
-
-
-
-
5
Amortization Of Stock Issuance Costs
-
-
-
-
-
-
0
0
0
-